• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves Impel NeuroPharma’s nasal spray for treating migraines

September 3, 2021 By Sean Whooley

Impel Neuropharma logo updatedImpel NeuroPharma (NSDQ:IMPL) announced today that the FDA approved its Trudhesa nasal spray for treating migraine in adults.

Seattle-based Impel NeuroPharma plans to launch Trudhesa commercially early next month. The company’s shares took a massive hit, though, dropping -19.3% at $18.65 per share by market close and continuing to slide down -0.8% at $18.50 after hours today.

Trudhesa (dihydroergotamine mesylate), previously known as INP104, treats migraine with or without aura in adults through a 0.725 mg per spray dosage, according to a news release.

Impel’s proprietary Precision Olfactory Delivery (POD) technology combines with Trudhesa to gently deliver dihydroergotamine mesylate (DHE) quickly to the bloodstream through the upper nasal space, bypassing the gut and potential absorption issues to offer rapid, sustained and consistent symptom relief without injection or infusion, even when administered hours after the onset of a migraine attack, the company said.

Impel NeuroPharma’s new drug application for Trudhesa cited results from the Phase 3, open-label pivotal safety study, STOP 301, which it said is the largest longitudinal study ever conducted with DHE using nasal spray delivery, treating more than 5,650 migraine attacks over 24 or 52 weeks.

Trudhesa was well tolerated and provided rapid, sustained and consistent symptom relief with no serious drug-related, treatment-emergent adverse events observed. The study showed that 38% of patients had pain freedom, 66% had pain relief and 52% had freedom from their most bothersome migraine symptom at two hours after their first dose. Among the most frequently reported related mild adverse events were nasal congestion (17.8%), nausea (6.8%), nasal discomfort (6.8%), abnormal olfactory test (6.8%) and vomiting (2.7%).

Pain relief started as early as 15 minutes after dosing for 16% of patients, with 93% of those who were pain-free at two hours remaining pain-free at 24 hours, plus 86% stayed pain-free through two days. Additionally, 84% of patients reported that Trudhesa was easy to use and that they preferred it over their current therapy.

“We are delighted with the approval of Trudhesa and are proud to offer the millions of Americans with migraine a non-oral, acute treatment option that may provide rapid, sustained, and consistent relief, even when taken late into a migraine attack,” Impel NeuroPharma chairman & CEO Adrian Adams said in the release. “The approval of Trudhesa marks the culmination of more than a decade of research and advanced engineering to pair the proven efficacy of DHE with our innovative POD technology. We are grateful for all the patients and investigators who participated in our clinical trials and who were instrumental in bringing this needed advancement to the migraine community.”

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Regulatory/Compliance Tagged With: FDA, Impel NeuroPharma Inc.

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS